Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Corticosteroids; Hydrocortisone; Triamcinolone
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms BREEZE-AD7
  • Sponsors Eli Lilly and Company; Eli Lilly Japan

Most Recent Events

  • 01 May 2023 Results assessing the long-term efficacy of baricitinib combined with topical corticosteroids (TCS) in adult patients from a Phase 3 study, BREEZE-AD7 (NCT03733301), enrolled in ongoing extension study, BREEZE-AD3 (NCT03334435), published in the Journal of the European Academy of Dermatology and Venereology.
  • 01 Jul 2021 Results of an analysis assessing the efficacy of baricitinib plus topical corticosteroids using functional measures of HRQoL, work productivity and life activities, symptom impact and treatment benefit in adults with moderate-to-severe AD with previous inadequate response to topical corticosteroids published in the Journal of the European Academy of Dermatology and Venereology
  • 23 Apr 2021 According to an Eli Lilly media release, these results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top